Benjamin Brannick, MD
Endocrinology, Diabetes & Metabolism · Memphis, TNNPI 1679718357
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 54 manufacturers reported payments, led by Xeris Pharmaceuticals, Inc. at 50.2% of the total.
Across 1,132 payments — averaging $73.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$42K
- Sanofi-aventis U.S. LLC$19K
- Corcept Therapeutics$3K
- Novo Nordisk$3K
- AstraZeneca$2K
- Lilly USA, LLC$2K
- plus $13K from 48 others
What the payments were for
- Consulting fees$12,90015%
- Speaking & faculty fees$39,23447%
- Travel & lodging$7,4869%
- Food & beverage$23,97629%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RECORLEV$39,603
- SOLIQUA 100/33$13,358
- TOUJEO$6,340
- Korlym$1,891
- GVOKE HYPOPEN$945
- Strensiq$930
- FARXIGA$446
- iLet Bionic Pancreas$444
- Prolia$349
- EVENITY$349
- Lupron Depot$320
- MINIMED 780G$247
- Minimed 670G System$246
- Ozempic$235
- Omnipod$220
- CeQur Simplicity$176
- DEXCOM G7 GSS (161)$128
- Kerendia$125
- TEPEZZA$124
- FreeStyle Libre Pro$117
How this compares
$83,681 in reported general payments places this provider in the 85th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 16 | $1,319,535 |
| OzempicSemaglutide | 685 | $793,164 |
| MounjaroTirzepatide | 493 | $587,049 |
| RecorlevLevoketoconazole | 13 | $519,766 |
| JardianceEmpagliflozin | 340 | $409,402 |
| TrulicityDulaglutide | 177 | $220,982 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 201 | $163,216 |
| FarxigaDapagliflozin Propanediol | 135 | $129,143 |
| Tresiba Flextouch U-100Insulin Degludec | 129 | $94,658 |
| Tresiba Flextouch U-200Insulin Degludec | 60 | $71,723 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 49 | $68,005 |
| RybelsusSemaglutide | 41 | $66,757 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $66,461 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 83 | $66,412 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 106 | $54,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga | $2,257 | $1,448,679151 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $2,718 | $895,298813 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,931 | $813,975699 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr, Glyxambi | $1,525 | $535,137454 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $41,979 | $519,76613 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $19,060 | $163,216201 claims |
| MerckJanuvia, Janumet | $138 | $69,74552 claims |
| Johnson & JohnsonInvokana | $224 | $22,38615 claims |
| AbbVieSynthroid | $1,093 | $13,066122 claims |
| BayerKerendia | $420 | $12,68012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Memphis
- Alan CohenMemphis$1.4M
- Shimon HararyMemphis$735K
- Samuel Dagogo-JackMemphis$407K
- Aidar GosmanovMemphis$138K
- Malini GuptaMemphis$91K
- Pedro VelasquezMemphis$21K
- Fariha SalmanMemphis$14K
- Maher GhawjiMemphis$13K
- Yunna JiangMemphis$12K
- Rabia RehmanMemphis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.